While historically listed with an "unknown status," recent data releases in late 2025 and early 2026 have clarified the safety profile that helped justify the Category 1 reclassification. Study Design: A randomized, placebo-controlled, double-blind Phase 1 pilot study
However, preclinical studies demonstrate therapeutic effects with once-daily or even less frequent administration, suggesting tissue distribution, receptor binding, or cellular signaling effects extend beyond plasma clearance
However, there is no strong clinical evidence showing it can heal a herniated disc in humans
Reconstitution reference U100 units to draw for each common TB-500 dose, by vial size, reconstituted with 2 mL of bacteriostatic water
Researchers classify it as a "stable gastric pentadecapeptide" because of its unusual stability in the harsh acidic environment of the stomach
CONTENTS AND OTHER INFORMATION What VITAMIN B12 DELAGRANGE 1000 micrograms/2 ml, injectable (IM) and drinkable solution contains - The active substance is : Cyanocobalamin